AstraZeneca has sold US and Canadian rights to its older breast cancer drug Zoladex to TerSera Therapeutics in a deal worth up to $320 million. The deal is good business for AstraZeneca ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback